Molecular Point-of-Care (mPOC) Market Reaches $1.8 Billion: Kalorama Report Spotlights Rapid PCR Innovation and Expanding Frontiers in STI and HAI Testing
ARLINGTON, Va., June 20, 2025 /PRNewswire/ — Kalorama Information, a leading authority in in vitro diagnostics (IVD) market research, has released Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029, estimating the global mPOC market at $1.8 billion in 2024. The report offers a comprehensive forecast through 2029, highlighting transformative opportunities in respiratory, sexually transmitted, and hospital-acquired infection diagnostics at or near the point of care.
'While the molecular point-of-care market saw unprecedented acceleration during the COVID-19 pandemic, Kalorama's latest analysis reveals it now stands on a firmer foundation with renewed growth expected,' said Justin Saeks, senior market analyst and report author. 'We anticipate an almost double-digit compound annual growth rate for the 'true' mPOC segment as demand spreads beyond COVID to broader respiratory panels, STIs, HAIs, and tropical diseases.'
Key Findings from the Report:
Respiratory testing dominates the market, with COVID-19, flu, strep, and RSV continuing to drive system adoption, particularly for combination tests. Growth expected in HAIs and STIs, although these will evolve more slowly due to testing infrastructure and workflow differences across care settings. 'True' mPOC segment revenues, which had recently declined, are projected to achieve a substantial CAGR from 2024 to 2029.
Kalorama differentiates between 'true' mPOC platforms and near-patient systems, offering detailed segmentation by company, region, and disease target. Abbott and Cepheid lead their respective segments.
True mPOC Systems: Compact, fast, CLIA-waived (or with waiver potential), and operable by non-lab personnel. Key players include Abbott (market leader), Roche, Cepheid, QuidelOrtho, BioFire, and Sekisui. Near-Patient Molecular Systems: Encompasses larger non-POC systems and smaller platforms with POC or near-POC potential. BioFire and Cepheid are major competitors, with Cepheid leading this segment.
Why It Matters Now
The report's release is timely as healthcare providers seek diagnostic solutions that balance speed, accuracy, and accessibility across both developed and resource-limited settings. mPOC systems bring the power of molecular testing to emergency departments, outpatient clinics, nursing homes, mobile labs, and even homes—enabling timely treatment decisions and improving care outcomes.
'POC molecular diagnostics represent one of the most important intersections between innovation and access in global health,' said Alisa Alvich, Marketing Director at Science and Medicine Group, Kalorama Information's parent company. 'Kalorama's analysis shows where this market is headed and what players must consider to stay competitive.'
Audience Impact
This research is essential for:
Product Managers and R&D leaders developing decentralized molecular platforms. Corporate strategy teams evaluating new market opportunities or CLIA-waived innovations. Investors and M&A professionals scouting high-growth segments or acquisition targets. Clinical lab and procurement teams optimizing test menus for decentralized care delivery.
With deep dives into market sizing, disease applications, regional dynamics, and competitive intelligence, Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 equips life sciences professionals with the insights needed to navigate a rapidly evolving diagnostics frontier.
Get the Report
Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 is now available for purchase at: https://kaloramainformation.com/product/molecular-point-of-care-mpoc-2024-2029/
For purchasing inquiries or to schedule a custom consultation, contact:Sheri Davie – Sales Director, Kalorama Informationsheri.davie@scienceandmedicinegroup.com
About Kalorama Information
Kalorama Information, part of Science and Medicine Group Inc., is a trusted publisher of market research exclusively focused on the healthcare industry. For over 25 years, Kalorama has delivered accurate, timely, and strategic intelligence to leaders in biotechnology, clinical diagnostics, in vitro diagnostics (IVD), pharmaceuticals, medical devices, and broader healthcare sectors.
Originally launched in 1998, Kalorama Information quickly established itself as a premier source of insight into U.S. and global medical markets. Today, Kalorama remains a leading authority on healthcare market dynamics, with a particular emphasis on IVD.
Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, an internationally recognized benchmark in the diagnostics field. Other reports published throughout the year cover these and other healthcare topics in greater detail. Our innovative approach to research, combined with deep industry expertise, has made Kalorama a go-to resource for top healthcare companies, strategic planners, investors, and media seeking authoritative market data and trends.
With a singular focus on healthcare, Kalorama continues to shape informed decision-making across the industry through comprehensive, evidence-based analysis.
Kalorama also works in coordination with other Science and Medicine Group brands, including BioInformatics, which focuses on life science markets and marketing, SDi, the leading source of information on the laboratory life science and analytical instrumentation industry and publisher of IBO, its twice-monthly newsletter, and IMV, which publishes reports and data on the medical imaging and clinical markets.
For more information about Kalorama Information and other services offered by Science and Medicine Group, please visit our website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Express
21 minutes ago
- Daily Express
Making nurses work 45 hours not the solution
Published on: Sunday, June 22, 2025 Published on: Sun, Jun 22, 2025 Text Size: Rather than imposing longer hours, Malaysia should invest in sustainable workforce solutions that respect nurses' welfare and dignity. NURSES are the backbone of healthcare worldwide and Malaysia is no exception. They serve on the frontlines in hospitals, clinics and community care settings, often working long hours to ensure patients receive timely and compassionate care. Their importance was highlighted during the Covid-19 pandemic when Malaysian nurses risked their health to care for thousands of patients. Despite their indispensable role, the government is considering increasing nurses' weekly work hours to 45. This policy aims to address workforce shortages and meet rising healthcare demands but has met with widespread concern. While the intent is commendable, increasing work hours without increasing support risks harming nurses' welfare, patient safety and healthcare quality. Globally, healthcare systems that prioritise strong protections for nurses typically maintain workweeks between 36 and 40 hours – striking a crucial balance between service demands and staff well-being. The United Kingdom: Nurses work around 37.5 hours weekly, with regulations limiting overtime and mandating rest breaks to prevent fatigue. The Royal College of Nursing advocates for safe working hours to uphold care quality. Australia: Nurses typically work 38 hours per week, with industrial awards ensuring fair shifts and rest. The Australian Nursing and Midwifery Federation warns that long shifts can compromise patients' safety as well as nurses. Singapore: Nurses generally have a 40-hour work week, with carefully managed shifts designed to minimise fatigue. The United States: Despite the prevalence of 12-hour shifts, total weekly hours generally remain between 36 and 40. The American Nurses Association highlights that exceeding these hours increases errors and dissatisfaction. In comparison, Malaysia's proposed 45-hour work week exceeds these standards, raising valid concerns. Advertisement Real cost and implications Burnout among nurses has been recognised by the World Health Organisation as an occupational phenomenon linked to chronic workplace stress. It manifests as emotional exhaustion, cynicism and reduced personal accomplishment. For nurses, this translates to diminished empathy, increased absenteeism and lower quality of care. Research confirms that extended shifts and work weeks correlate with higher burnout. A study across 12 countries found that nurses working over 12-hour shifts reported significantly higher burnout levels and poorer care quality. Another study showed nurses working more than 40 hours per week faced increased risks of depression and anxiety. Prolonged work hours can also endanger nurses physically. Fatigue impairs cognitive function, increasing the chance of errors and accidents. Nurses working longer shifts experience higher rates of musculoskeletal injuries and needle-stick incidents. Additionally, it causes chronic sleep deprivation, a frequent outcome associated with cardiovascular disease, obesity and a weakened immune system. Multifaceted problem Malaysia is grappling with a severe nursing shortage, with over 12,000 vacancies in public healthcare reported by the Health Ministry. This shortage forces existing nurses to work longer hours and manage heavier patient loads. Simply increasing work hours without hiring more staff only shifts the burden onto nurses, accelerating burnout and turnover. Research shows poor working conditions and excessive workloads are key reasons nurses quit. Turnover is costly, including recruitment and training expenses. It also disrupts patient care continuity and weakens institutional knowledge. Patients' safety at risk Patient safety is closely tied to nurses' working hours and staffing levels. Nurses working beyond 12-hour shifts are twice as likely to make errors. Each additional hour over 40 per week increases the risk of adverse events. Fatigue impairs decision-making, vigilance and reaction times critical to safe care. Low nurse-to-patient ratios increase mortality, complications and hospital stay lengths. Increasing work hours without improving staffing ratios dilutes nurses' ability to provide quality care. Over 90% of nurses in Malaysia are women, many of whom juggle demanding professional roles with unpaid caregiving at home. This 'double burden' is only intensified by extended work hours. This imbalance increases stress and work-family conflict, especially among younger nurses and mothers, contributing to higher attrition rates. Longer work hours also reduce time for continuing professional development (CPD), which is highly required for all nurses. CPD is essential for maintaining clinical skills and improving patient outcomes. Without adequate time for learning, nurses face professional stagnation, which risks the quality of healthcare delivery. Ethical and legal considerations Malaysia upholds international labour standards that emphasise fair working conditions, reasonable work hours and the protection of workers' rights. Implementing a 45-hour work week for nurses could contradict these principles, potentially breaching ethical obligations and legal commitments. Such a policy not only risks compromising nurses' well-being but also undermines their professional dignity, equity and the broader values of social justice in the healthcare workforce. Alternatives solutions To improve healthcare sustainably, Malaysia should: Maintain a 40-hour work week in line with international norms. Enhance recruitment and retention by improving pay, benefits and working conditions. Adopt flexible shift scheduling to reduce fatigue and burnout. Provide comprehensive mental health support and burnout prevention programmes. Ensure nurses have protected time for CPD and career development. Nurses are the lifeblood of Malaysia's healthcare system. Extending their work week to 45 hours will threaten their health, patient safety and the overall quality of care. Rather than imposing longer hours, Malaysia should invest in sustainable workforce solutions that respect nurses' welfare and dignity. Only by doing so can we build a resilient healthcare system capable of delivering safe, compassionate care to all Malaysians. Zainudin Rozali is dean at the Faculty of Nursing, IJN University College The views expressed here are the views of the writer and do not necessarily reflect those of the Daily Express. If you have something to share, write to us at: [email protected]
The Star
4 hours ago
- The Star
Teens push for digital detox trend
Working on their vision: LifeUp Organisation founders Li Xuan and her brother Yu Wei (right) interviewing a family about their experience with digital detox during one of their programmes this month. Siblings turn their struggle into a movement using interactive games and more JOHOR BARU: Like many teens, Liew Li Xuan developed an unhealthy screen addiction and was glued to her smartphone during the Covid-19 pandemic, which affected her grades and even sparked frequent arguments with her father. Now, the 18-year-old has turned her personal struggle into a movement to help other youths unplug from the digital world. 'Back then, I was addicted to doom-scrolling and spent excessive amounts of time online. I often argued with my father, who intervened by changing our home's Wi-Fi password and confiscating my phone. 'Although I was furious at the time, it was also a turning point. After some reflection, I realised I had to regain control of my life rather than let my unhealthy habits take over,' she said in an interview. Together with her 16-year-old brother Yu Wei, the siblings started LifeUp Organisation two years ago to promote digital detox and healthier online habits among children and teenagers. With the support from their father, the teens began conducting online and in-person activities to encourage digital well-being, tackle cyberbullying and educate youths on online scams. To date, they have attracted participants as young as 10 and older adults, using interactive methods such as mini games and puzzles to convey their message. 'We have seen that even children under 12, who have access to social media, are affected by curated content, which can harm their self-worth and confidence. 'This is why our work is important – to help them take a step back and live more intentionally,' said Li Xuan. She added that one of their most effective initiatives is their regular screen-time reduction challenge. 'We encouraged people to cut their screen time by at least 20%, but some managed to reduce it by up to 95% through conscious effort. That really encouraged us to keep going,' she said. The siblings fund their programmes through self-raised funds and sponsorships from multinational companies. Beyond digital detox workshops, the siblings, along with eight other volunteers, have also organised community service activities at charity homes in Johor Baru. Li Xuan's work also led to her appointment as a speaker under the Malaysian Communications and Multimedia Commission's Safe Internet Campaign, where she gives talks to pupils in Chinese schools in Johor on internet safety and healthy digital habits. 'Our group has recently started a podcast in hopes of reaching out to more people about the importance of taking a digital detox,' she added. Li Xuan, who will be pursuing A-Levels at a private college in Selangor this August, said she has gained valuable leadership and organisational experience through her activities. 'As my peers and I further our studies across the country, we hope to start similar movements in our respective campuses,' she added. Now that she has turned 18, Li Xuan hopes to formally register the group under the Registrar of Societies to expand their programmes and reach more communities. 'I want to continue this journey and inspire more young people to take charge of their digital wellbeing,' she said.
Malaysian Reserve
a day ago
- Malaysian Reserve
Molecular Point-of-Care (mPOC) Market Reaches $1.8 Billion: Kalorama Report Spotlights Rapid PCR Innovation and Expanding Frontiers in STI and HAI Testing
ARLINGTON, Va., June 20, 2025 /PRNewswire/ — Kalorama Information, a leading authority in in vitro diagnostics (IVD) market research, has released Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029, estimating the global mPOC market at $1.8 billion in 2024. The report offers a comprehensive forecast through 2029, highlighting transformative opportunities in respiratory, sexually transmitted, and hospital-acquired infection diagnostics at or near the point of care. 'While the molecular point-of-care market saw unprecedented acceleration during the COVID-19 pandemic, Kalorama's latest analysis reveals it now stands on a firmer foundation with renewed growth expected,' said Justin Saeks, senior market analyst and report author. 'We anticipate an almost double-digit compound annual growth rate for the 'true' mPOC segment as demand spreads beyond COVID to broader respiratory panels, STIs, HAIs, and tropical diseases.' Key Findings from the Report: Respiratory testing dominates the market, with COVID-19, flu, strep, and RSV continuing to drive system adoption, particularly for combination tests. Growth expected in HAIs and STIs, although these will evolve more slowly due to testing infrastructure and workflow differences across care settings. 'True' mPOC segment revenues, which had recently declined, are projected to achieve a substantial CAGR from 2024 to 2029. Kalorama differentiates between 'true' mPOC platforms and near-patient systems, offering detailed segmentation by company, region, and disease target. Abbott and Cepheid lead their respective segments. True mPOC Systems: Compact, fast, CLIA-waived (or with waiver potential), and operable by non-lab personnel. Key players include Abbott (market leader), Roche, Cepheid, QuidelOrtho, BioFire, and Sekisui. Near-Patient Molecular Systems: Encompasses larger non-POC systems and smaller platforms with POC or near-POC potential. BioFire and Cepheid are major competitors, with Cepheid leading this segment. Why It Matters Now The report's release is timely as healthcare providers seek diagnostic solutions that balance speed, accuracy, and accessibility across both developed and resource-limited settings. mPOC systems bring the power of molecular testing to emergency departments, outpatient clinics, nursing homes, mobile labs, and even homes—enabling timely treatment decisions and improving care outcomes. 'POC molecular diagnostics represent one of the most important intersections between innovation and access in global health,' said Alisa Alvich, Marketing Director at Science and Medicine Group, Kalorama Information's parent company. 'Kalorama's analysis shows where this market is headed and what players must consider to stay competitive.' Audience Impact This research is essential for: Product Managers and R&D leaders developing decentralized molecular platforms. Corporate strategy teams evaluating new market opportunities or CLIA-waived innovations. Investors and M&A professionals scouting high-growth segments or acquisition targets. Clinical lab and procurement teams optimizing test menus for decentralized care delivery. With deep dives into market sizing, disease applications, regional dynamics, and competitive intelligence, Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 equips life sciences professionals with the insights needed to navigate a rapidly evolving diagnostics frontier. Get the Report Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 is now available for purchase at: For purchasing inquiries or to schedule a custom consultation, contact:Sheri Davie – Sales Director, Kalorama About Kalorama Information Kalorama Information, part of Science and Medicine Group Inc., is a trusted publisher of market research exclusively focused on the healthcare industry. For over 25 years, Kalorama has delivered accurate, timely, and strategic intelligence to leaders in biotechnology, clinical diagnostics, in vitro diagnostics (IVD), pharmaceuticals, medical devices, and broader healthcare sectors. Originally launched in 1998, Kalorama Information quickly established itself as a premier source of insight into U.S. and global medical markets. Today, Kalorama remains a leading authority on healthcare market dynamics, with a particular emphasis on IVD. Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, an internationally recognized benchmark in the diagnostics field. Other reports published throughout the year cover these and other healthcare topics in greater detail. Our innovative approach to research, combined with deep industry expertise, has made Kalorama a go-to resource for top healthcare companies, strategic planners, investors, and media seeking authoritative market data and trends. With a singular focus on healthcare, Kalorama continues to shape informed decision-making across the industry through comprehensive, evidence-based analysis. Kalorama also works in coordination with other Science and Medicine Group brands, including BioInformatics, which focuses on life science markets and marketing, SDi, the leading source of information on the laboratory life science and analytical instrumentation industry and publisher of IBO, its twice-monthly newsletter, and IMV, which publishes reports and data on the medical imaging and clinical markets. For more information about Kalorama Information and other services offered by Science and Medicine Group, please visit our website.
